Advertisement

Progress in Experimental Systemic Active Immunotherapy of Cancer

  • G. Mathé
  • I. Florentin
  • M. Bruley-Rosset
  • N. Kiger
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 75)

Abstract

A short review is presented of animal models used in cancer immunotherapy. Attention is focused on spontaneous canine tumors submitted to active immunotherapy after surgery, and on the use of immunorestoring agents to prevent spontaneous tumors in age-immunodepressed mice.

Keywords

Cancer Immunotherapy Spontaneous Tumor Active Immunotherapy L1210 Leukemia Systemic Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bekesi JG, Holland JF (1974) Combined chemotherapy and immunotherapy of transplantable and spontaneous murine leukemia in DBA/2 and AkR mice. Recent Results Cancer Res 47:357–369Google Scholar
  2. 2.
    Bonadonna G, Mathé G, Salmon SE (eds) (1979) Adjuvant therapies and markers of post-surgical minimal residual disease. II. Adjuvant therapies and markers of the various primary tumors. Recent Results Cancer Res 68Google Scholar
  3. 3.
    Bruley-Rosset M, Florentin I, Kiger N, Davigny M, Mathé G (1978) Effects of bacillus Calmette-Guérin and levamisole on immune responses in young adult and age-immuno-depressed mice. Cancer Treat Rep 62:1641–1650PubMedGoogle Scholar
  4. 4.
    Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Davigny M, Mathé G (1980) Age-related changes of the immune response and immunorestoration by stimulating agents. In: Doria G, Eshkol A (eds) The immune system, function and therapy of dysfunction. Academic Press, New York, pp 171–187Google Scholar
  5. 5.
    Bruley-Rosset M, Florentin I, Kiger N, Schulz J, Mathé G (1979) Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology 38:75–83PubMedGoogle Scholar
  6. 6.
    Coid CR (1978) Selection of animals suitable for biomedical investigations. J Soc Med 71:675–677Google Scholar
  7. 7.
    Fortner JG (1977) Management of recurrent malignant melanoma. In: Third International Symposium on Oncology, Teheran 4–8 March, p 60 (abstr 21)Google Scholar
  8. 8.
    Huchet R, Lhéritier J (1976) Non-specific immunodepression induced by tumor-cell extracts. Recent Results Cancer Res 56:65–71PubMedGoogle Scholar
  9. 9.
    International Meeting on Comparative Therapeutic Trials, Paris, January 1978. In: Lortat-Jacob JL, Mathé G, Servier J (eds). Biomedicine 28 (special issue)Google Scholar
  10. 10.
    Kennel SJ, Tsakeres F, Kelly PA, Allison DP (1978) Defective C-type retrovirus particles secreted by L1210 leukemia cells. Cancer Res 38:4574–4579PubMedGoogle Scholar
  11. 11.
    Lacour F, Delage G, Chianale C (1975) Reduced incidence of spontaneous mammary tumors in C3H/He mice after treatment with polyadenylate-polyuridylate. Science 187:256–257PubMedCrossRefGoogle Scholar
  12. 12.
    Lemonde P (1974) Inhibition de la néoplasie par stimulation de l’immunité. Aspects expérimentaux. Union Med Can 103:1716–1728PubMedGoogle Scholar
  13. 13.
    Mathé G (1976) Cancer active immunotherapy: Immunoprophylaxis and immunorestoration. An introduction. Recent Results Cancer Res 55Google Scholar
  14. 14.
    Mathé G (1978) Systemic active immunotherapy is shifting from the middle ages to a renaissance period. I. The multiplication of randomized trials showing significant effect of active immunotherapy on residual minimal disease. Cancer Immunol Immunother 5:149–152CrossRefGoogle Scholar
  15. 15.
    Mathé G, Halle-Pannenko I. Bourut C (1973) Active immunotherapy in spontaneous leukemia of AkR mice. Exp Hematol 1:110–114PubMedGoogle Scholar
  16. 16.
    Milas L, Hunter N, Basic I, Rodney Withers H (1974) Complete regressions of an established murine fibrosarcoma induced by systemic application of Corynebacterium granulosum. Cancer Res 34:2470–2475PubMedGoogle Scholar
  17. 17.
    Nathrath WBJ (1978) Organ and tumour antigens in malignant disease: A review. J R Soc Med 71:755–671PubMedGoogle Scholar
  18. 18.
    Nicolson GL (1979) Cancer metastasis. Sci Am 240:50–60CrossRefGoogle Scholar
  19. 19.
    Owen LN, Bostock DE (1974) Effects of intravenous BCG in normal dogs, and dogs with spontaneous osteosarcoma. Eur J Cancer 10:775–780PubMedGoogle Scholar
  20. 20.
    Owen LN, Bostock DE, Lavelle RB (1977) Studies on therapy of osteosarcoma in dogs using BCG vaccine. J Am Vet Radiol Soc 18:27–29CrossRefGoogle Scholar
  21. 21.
    Piessens WF, Lachapelle FL, Legros N, Heuson JC (1970) Facilitation of rat mammary tumour growth by BCG. Nature 228:1210–1211PubMedCrossRefGoogle Scholar
  22. 22.
    Renoux G, Kassel RL, Renoux M, Fiore NC, Guillamin JM, Palat A (1977) Immunomodulation by levamisole in normal and leukemic mice: Evidence for a serum transfer. In: Chingos MA (ed) Immunomodulation of host immune resistance in the prevention or treatment of induced neoplasias. U.S. Government Printing Office, Washington, pp 45–51Google Scholar
  23. 23.
    Salmon SS, Jones SE (eds) (1979) Adjuvant therapy of cancer. Grune and Stratton, New YorkGoogle Scholar
  24. 24.
    Terry WD, Windhorst D (eds) (1978) Immunotherapy of cancer: Present status of trials in man. Raven, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • G. Mathé
  • I. Florentin
  • M. Bruley-Rosset
  • N. Kiger

There are no affiliations available

Personalised recommendations